|Positive WB detected in||mouse thymus tissue, mouse spleen tissue|
|Positive IHC detected in||human tonsillitis tissue, human lymphoma tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive IF detected in||human tonsillitis tissue|
|Western Blot (WB)||WB : 1:300-1:1000|
|Immunohistochemistry (IHC)||IHC : 1:400-1:1600|
|Immunofluorescence (IF)||IF : 1:50-1:500|
|Sample-dependent, check data in validation data gallery|
The immunogen of 18106-1-AP is PD-1/CD279 Fusion Protein expressed in E. coli.
|Tested Reactivity||human, mouse|
|Cited Reactivity||human, mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||PD-1/CD279 fusion protein Ag12470|
|Full Name||programmed cell death 1|
|Calculated molecular weight||288 aa, 32 kDa|
|Observed molecular weight||47-55 kDa|
|GenBank accession number||BC074740|
|Gene ID (NCBI)||5133|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
Programmed cell death 1 (PD-1, also known as CD279) is an immunoinhibitory receptor that belongs to the CD28/CTLA-4 subfamily of the Ig superfamily. It is a 288 amino acid (aa) type I transmembrane protein composed of one Ig superfamily domain, a stalk, a transmembrane domain, and an intracellular domain containing an immunoreceptor tyrosine-based inhibitory motif (ITIM) as well as an immunoreceptor tyrosine-based switch motif (ITSM) (PMID: 18173375). PD-1 is expressed during thymic development and is induced in a variety of hematopoietic cells in the periphery by antigen receptor signaling and cytokines (PMID: 20636820). Engagement of PD-1 by its ligands PD-L1 or PD-L2 transduces a signal that inhibits T-cell proliferation, cytokine production, and cytolytic function (PMID: 19426218). It is critical for the regulation of T cell function during immunity and tolerance. Blockade of PD-1 can overcome immune resistance and also has been shown to have antitumor activity (PMID: 22658127; 23169436). It has been reported that PD-1 is heavily glycosylated and migrates with an apparent molecular mass of 47-55 kDa on SDS-PAGE , which is larger than its predicted mass of 32 kDa (PMID: 8671665; 17640856; 17003438).
PD-1/PD-L1 Axis, Rather Than High-Mobility Group Alarmins or CD8+ Tumor-Infiltrating Lymphocytes, Is Associated With Survival in Head and Neck Squamous Cell Carcinoma Patients Who Received Surgical Resection.
NPJ Precis Oncol
Immunological markers predict the prognosis of patients with squamous non-small cell lung cancer.
Co-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinoma.
World J Gastrointest Oncol
Synergistic anti-liver cancer effects of curcumin and total ginsenosides.
Int J Biol Markers
Expression of PD-1/PD-L1 in head and neck squamous cell carcinoma and its clinical significance.